Functional genome and proteome analyses of cutaneous autoimmune diseases

Current Pharmaceutical Design

Volumn 12, Issue 29, 2006, Pages 3787-3798

  Trcka, J ^a   Kunz, Manfred ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Cutaneous autoimmune diseases; DNA microarrays; mRNA expression profiles; Proteome analysis

Indexed keywords

CELECOXIB; CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; METHYLPREDNISOLONE; NIFLUMIC ACID; PIMECROLIMUS; PROTEOME; RECOMBINANT INTERLEUKIN 11;

ALOPECIA AREATA; APOPTOSIS; AUTOIMMUNE DISEASE; DERMATOLOGY; FUNCTIONAL GENOMICS; FUNCTIONAL PROTEOMICS; GENE EXPRESSION; GENOME; HUMAN; INFLAMMATORY DISEASE; LUPUS ERYTHEMATOSUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; SYSTEMIC SCLEROSIS; VITILIGO;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CYTOKINES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME, HUMAN; GENOMICS; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOME; PROTEOMICS; PSORIASIS; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN DISEASES;

EID: 33749857180     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778559777     Document Type: Review

References (101)

1. Carroll M. Innate immunity in the etiopathology of autoimmunity. Nat Immunol 2001; 2(12): 1089-1090.
2. Christen U, von Herrath MG. Initiation of autoimmunity. Curr Opin Immunol 2004; 16(6): 759-767.
3. Bos JD, de Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20(1): 40-46.
4. Bowcock AM. The Genetics of Psoriasis and Autoimmunity. Annu Rev Genomics Hum Genet 2005; 6: 93-122.
5. Moser KL, Gaffney PM, Grandits ME, Emamian ES, Machado DB, Baechler EC, et al. The use of microarrays to study autoimmunity. J Investig Dermatol Symp Proc 2004; 9(1): 18-22.
6. Samuelsson L, Enlund F, Torinsson A, Yhr M, Inerot A, Enerback C, et al. A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach. Hum Genet 1999; 105(6): 523-529.
7. Jeffes EW, III, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995; 104(2): 183-188.
8. Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993; 14(2): 69-74.
9. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002; 12(6): 618-622.
10. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996; 98(8): 1878-1887.
11. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9(1): 40-46.
12. Vollmer S, Menssen A, Prinz JC. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol 2001; 117(5): 1296-1301.
13. Borgato L, Puccetti A, Beri R, Codella O, Frigo A, Simeoni S, et al. The T cell receptor repertoire in psoriatic synovitis is restricted and T lymphocytes expressing the same TCR are present in joint and skin lesions. J Rheumatol 2002; 29(9): 1914-1919.
14. Prinz JC. Disease mimicry - a pathogenetic concept for T cell-mediated autoimmune disorders triggered by molecular mimicry? Autoimmun Rev 2004; 3(1): 10-15.
15. Kunz M, Ibrahim SM, Koczan D, Scheid S, Thiesen HJ, Gross G. DNA microarray technology and its applications in dermatology. Exp Dermatol 2004; 13(10): 593-606.
16. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001; 10(17): 1793-1805.
17. Oestreicher JL, Walters IB, Kikuchi T, Gilleaudeau P, Surette J, Schwertschlag U, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001; 1(4): 272-287.
18. Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003; 13(1): 69-78.
19. Gu J, Marker-Hermann E, Baeten D, Tsai WC, Gladman D, Xiong M, et al. A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology (Oxford) 2002; 41(7): 759-766.
20. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, Krentz H, et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005; 15(4): 251-257.
21. Li G, Domenico J, Lucas JJ, Gelfand EW. Identification of multiple cell cycle regulatory functions of p57Kip2 in human T lymphocytes. J Immunol 2004; 173(4): 2383-2391.
22. Brown MP, Grundy WN, Lin D, Cristianini N, Sugnet CW, Furey TS, et al. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci USA 2000; 97(1): 262-267.
23. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002; 119(4): 876-887.
24. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56(7): 481-490.
25. Nath SK, Kilpatrick J, Harley JB. Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol 2004; 16(6): 794-800.
26. Maas K, Chan S, Parker J, Slater A, Moore J, Olsen N, et al. Cutting edge: molecular portrait of human autoimmune disease. J Immunol 2002; 169(1): 5-9.
27. Rosen A, Casciola-Rosen L. Clearing the way to mechanisms of autoimmunity. Nat Med 2001; 7(6): 664-665.
28. Mandel M, Gurevich M, Pauzner R, Kaminski N, Achiron A. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol 2004; 138(1): 164-170.
29. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000; 165(11): 6635-6643.
30. Pereira E, Tamia-Ferreira MC, Cardoso RS, Mello SS, Sakamoto-Hojo ET, Passos GA, et al. Immunosuppressive therapy modulates T lymphocyte gene expression in patients with systemic lupus erythematosus. Immunology 2004; 113(1): 99-105.
31. Xu L, Zhang L, Yi Y, Kang HK, Datta SK. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 2004; 10(4): 411-415.
32. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Moser K, Ortmann WA, et al. Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation. Genes Immun 2004; 5(5): 347-353.
33. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100(5): 2610-2615.
34. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003; 36(8): 481-490.
35. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003; 4(3): 177-186.
36. Qing X, Putterman C. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2004; 3(7-8): 505-509.
37. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197(6): 711-723.
38. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982; 25(4): 401-406.
39. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216(4544): 429-431.
40. Ronnblom LE, Alm GV, Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991; 30(4): 537-540.
41. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197(6): 777-788.
42. Crow MK, George S, Paget SA, Ly N, Woodward R, Fry K, et al. Expression of an interferon-alpha gene program in SLE. Arthritis Rheum 2002; 46(Suppl.): S281.
43. Wakeland EK, Wandstrat AE, Liu K, Morel L. Genetic dissection of systemic lupus erythematosus. Curr Opin Immunol 1999; 11(6): 701-707.
44. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001; 15(3): 397-408.
45. Balomenos D, Carvalho-Pinto C, Martinez A. Still waiting for the end. The promise of genomics and proteomics for autoimmune diseases. EMBO 2002; 3(2): 104-107.
46. Steen VD, Medsger TA, Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43(11): 2437-2444.
47. Ahmed SS, Tan FK. Identification of novel targets in scleroderma: update on population studies, cDNA arrays, SNP analysis, and mutations. Curr Opin Rheumatol 2003; 15(6): 766-771.
48. Jeoung DI, Bong LE, Lee S, Lim Y, Lee DY, Kim J, et al. Autoantibody to DNA binding protein B as a novel serologic marker in systemic sclerosis. Biochem Biophys Res Commun 2002; 299(4): 549-554.
49. Strehlow DR. The promise of transcription profiling for understanding the pathogenesis of scleroderma. Curr Rheumatol Rep 2000; 2(6): 506-511.
50. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100(21): 12319-12324.
51. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X, et al. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002; 46(7): 1857-1865.
52. Zhou X, Tan FK, Xiong M, Milewicz DM, Feghali CA, Fritzler MJ, et al. Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J Immunol 2001; 167(12): 7126-7133.
53. Tan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 2005; 52(3): 865-876.
54. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000; 43(4): 889-893.
55. Rottoli P, Magi B, Perari MG, Liberatori S, Nikiforakis N, Bargagli E, et al. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005; 5(5): 1423-1430.
56. Ohba T, McDonald JK, Silver RM, Strange C, LeRoy EC, Ludwicka A. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor. Am J Respir Cell Mol Biol 1994; 10(4): 405-412.
57. Ishii Y, Hirano K, Morishima Y, Masuyama K, Goto Y, Nomura A, et al. Early molecular and cellular events of oxidant-induced pulmonary fibrosis in rats. Toxicol Appl Pharmacol 2000; 167(3): 173-181.
58. Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 2003; 29(2): 211-237.
59. Zhou X, Tan FK, Wang N, Xiong M, Maghidman S, Reveille JD, et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003, 48(9): 2585-2592.
60. Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, Schmidt RE, et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 2004; 50(5): 1561-1565.
61. Nordlund JJ, Ortonne JP. Vitiligo vulgaris. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP, ed. The pigmentary system. Oxford University Press, New York, 1998; 513-551.
62. Hann SK, Nordlund JJ. Vitiligo: a comprehensive monograph on basic and clinical science. Blackwell Science, Oxford, United Kingdom, 2005.
63. Hafez M, Sharaf L, Abd el-Nabi SM. The genetics of vitiligo. Acta Derm Venereol 1983; 63(3): 249-251.
64. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16(3): 208-214.
65. Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993; 129(8): 994-998.
66. Nadi SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet 1994; 55(5): 981-990.
67. Silvan M. The psychological aspects of vitiligo. Cutis 2004; 73(3): 163-167.
68. Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005, 152(6): 1165-1172.
69. Austin M. Fighting and living with vitiligo. J Am Acad Dermatol 2004; 51(1 Suppl): S7-S8.
70. Hartmann A, Brocker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004; 64(1): 89-107.
71. Arroyo MP, Tift L. Vitiligo therapy: where are we now? J Drugs Dermatol 2003; 2(4): 404-408.
72. Grimes PE. White patches and bruised souls: advances in the pathogenesis and treatment of vitiligo. J Am Acad Dermatol 2004; 51(1 Suppl): S5-S7.
73. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16(2): 90-100.
74. Kemp EH. Autoantibodies as diagnostic and predictive markers of vitiligo. Autoimmunity 2004; 37(4): 287-290.
75. Naughton GK, Eisinger M, Bystryn JC. Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983; 158(1): 246-251.
76. Ogg GS, Rod DP, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188(6): 1203-1208.
77. Kemp EH, Waterman EA, Weetman AP. Immunological pathomechanisms in vitiligo. Expert Rev Mol Med 2001; 2001: 1-22.
78. Trcka J, Moroi Y, Clynes RA, Goldberg SM, Bergtold A, Perales MA, et al. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity 2002; 16(6): 861-868.
79. Cunliffe WJ, Hall R, Newell DJ, Stevenson CJ. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 1968: 80(3): 135-139.
80. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38(5 Pt 1): 647-666.
81. Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001; 34(1): 65-77.
82. Blomhoff A, Kemp EH, Gawkrodger DJ, Weetman AP, Husebye ES, Akselsen HE, et al. CTLA4 polymorphisms are associated with vitiligo, in patients with concomitant autoimmune diseases. Pigment Cell Res 2005; 18(1): 55-58.
83. Majumder PP, Das SK, Li CC. A genetical model for vitiligo. Am J Hum Genet 1988; 43(2): 119-125.
84. Arcos-Burgos M, Parodi E, Salgar M, Bedoya E, Builes J, Jaramillo D, et al. Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. Hum Genet 2002; 110(4): 334-342.
85. Zhang XJ, Liu JB, GW JP, Li M, Xiong QG, Wu HB, et al. Characteristics of genetic epidemiology and genetic models for vitiligo. J Am Acad Dermatol 2004; 51(3): 383-390.
86. Nath SK, Kelly JA, Namjou B, Lam T, Bruner GR, Scofield RH, et al. Evidence for a susceptibility gene, SLEVI, on chromosome 17p13 in families with vitiligo-related systemic 1upus erythematosus. Am J Hum Genet 2001; 69(6): 1401-1406.
87. Alkhateeb A, Stetler GL, Old W, Talbert J, Uhlhorn C, Taylor M, et al. Mapping of an autoimmunity susceptibility locus (AISI) to chromosome 1p31.3-p32.2. Hum Mol Genet 2002; 11(6): 661-667.
88. Fain PR, Gowan K, LaBerge GS, Alkhateeb A, Stetler GL, Talbert J, et al. A genomewide screen for generalized vitiligo: confirmation of AISI on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Genet 2003; 72(6): 1560-1564.
89. Spritz RA, Gowan K, Bennett DC, Fain PR. Novel vitiligo susceptibility loci on chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEVI on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet 2004; 74(1): 188-191.
90. Chen JJ, Huang W, Gui JP, Yang S, Zhou FS, Xiong QG, et al. A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families. Am J Hum Genet 2005; 76(6): 1057-1065.
91. McElwee K, Freyschmidt-Paul P, Ziegler A, Happle R, Hoffmann R. Genetic susceptibility and severity of alopecia areata in human and animal models. Eur J Dermatol 2001, 11(1): 11-16.
92. Carroll JM, McElwee KJ, King E, Byrne MC, Sundberg JP. Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol 2002; 119(2): 392-402.
93. Lueking A, Huber O, Wirths C, Schulte K, Stieler KM, Blume-Peytavi U, et al. Profiling of alopecia areata autoantigens based on protein microarray technology. Mol Cell Proteomics 2005; 4(9): 1382-1390.
94. Fathman CG, Soares L, Chan SM, Utz PJ. An array of possibilities for the study of autoimmunity. Nature 2005; 435(7042): 605-611.
95. Chan SM, Ermann J, Su L, Fathman CG, Utz PJ. Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med 2004; 10(12): 1390-1396.
96. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002; 8(3): 295-301.
97. Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, et al. Laser capture microdissection: molecular analysis of tissue. Science 1997; 278(5342): 1481,1483.
98. Cope AP, Feldmann M. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr Opin Immunol 2004; 16(6): 780-786.
99. Callanan M. Mining the probiotic genome: advanced strategies, enhanced benefits, perceived obstacles. Curr Pharm Des 2005; 11(1): 25-36.
100. Christopherson KW 2nd, Hromas RA. Endothelial chemokines in autoimmune disease. Curr Pharm Des 2004; 10(2): 145-54.
101. Eggert M, Kluter A, Zettl UK, Neeck G. Transcription factors in autoimmune diseases. Curr Pharm Des 2004; 10(23): 2787-96.